search
Back to results

Pediatric Teleneuromodulation

Primary Purpose

Cerebral Palsy (CP)

Status
Active
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Soterix 1x1 tDCS LTE Stimulator Device Model 1401
Sponsored by
University of Wisconsin, Madison
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Cerebral Palsy (CP) focused on measuring Children with cerebral palsy, Remote transcranial direct current stimulation (tDCS), Non-invasive brain stimulation (NIBS)

Eligibility Criteria

8 Years - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged between 8 years 0 days and 17 years 365 days
  • Children with a history of perinatal brain bleed/stroke
  • Receptive language function to follow two-step commands
  • Able to give informed assent along with the informed consent of the legal guardian
  • Intentional about representing the sub-population of children with CP who experience intellectual disability (2/10 participants with mild intellectual disabilities will be recruited)
  • ≥ 10 degrees of active motion at the metacarpophalangeal joint
  • Children who have had surgeries, which may influence motor function e.g.- tendon transfer, will be included, yet surgical history will be documented and included in any publication within a participant characteristics table.

Exclusion Criteria:

  • Inaccessibility to internet and a working computer/laptop/device.
  • Implants
  • Neoplasm
  • Metabolic Disorders
  • Epilepsy
  • Seizure within two years preceding the study
  • Acquired Traumatic Brain Injury
  • Pregnancy
  • Indwelling metal or incompatible medical devices
  • Evidence of skin disease or skin abnormalities
  • Botulinum toxin or Phenol block within [six-months] preceding the study
  • Disorder of Cellular Migration and Proliferation
  • Centrally Acting Agent

Sites / Locations

  • University of Wisconsin

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Children diagnosed with stroke/brain bleed

Arm Description

Male and females aged 8 to 21 with established diagnosis of stroke/brain bleed who are US residents.

Outcomes

Primary Outcome Measures

Status/Safety Assessment
Before stimulation, the study team will work with the participant to fill out a status survey. In the survey, participants will be asked to report the severity of events they may experience. Since investigators are working with the pediatric population, the investigator makes the final decision on the likelihood of an event being related to the tDCS intervention versus the participant's environment. Serious adverse events, falling in the 3-5 categories (1-unrelated, 2- unlikely, 3- possible, 4- probable, 5- definite) will be considered related to the study. This determination is made with the parent/caregiver as witnesses and confirmed by the parent/caregiver.
Status/Safety Assessment
During stimulation, the study team will work with the participant to fill out a status survey. In the survey, participants will be asked to report the severity of events they may experience. Since investigators are working with the pediatric population, the investigator makes the final decision on the likelihood of an event being related to the tDCS intervention versus the participant's environment. Serious adverse events, falling in the 3-5 categories (1-unrelated, 2- unlikely, 3- possible, 4- probable, 5- definite) will be considered related to the study. This determination is made with the parent/caregiver as witnesses and confirmed by the parent/caregiver.
Status/Safety Assessment
After stimulation, the study team will work with the participant to fill out a status survey. In the survey, participants will be asked to report the severity of events they may experience. Since investigators are working with the pediatric population, the investigator makes the final decision on the likelihood of an event being related to the tDCS intervention versus the participant's environment. Serious adverse events, falling in the 3-5 categories (1-unrelated, 2- unlikely, 3- possible, 4- probable, 5- definite) will be considered related to the study. This determination is made with the parent/caregiver as witnesses and confirmed by the parent/caregiver.
Change in tDCS headgear location
To evaluate the quality of device setup, we will measure any changes or movement of the headgear. To do this, we will mark the starting and ending location of the headgear and measure the distance between the two. It will be reported if the headgear moved in any participants and the average displacement.
Change in responses to ease of set up survey
To evaluate the feasibility of remotely monitored-tDCS, the difficulty of each step will be measured on an ordinal 3-point scale. A lower score will correspond with a lower difficulty setting. Average difficulty will be compared throughout all sessions to indicate any improvement throughout the study.
Change in responses to comfort survey
To evaluate the comfort of the device, participants will be asked a question on an ordinal 4-point scale. A lower score corresponds with a higher comfortability.
Medical Record Review at 6 months
To assess medical status and the potential for new onset seizures, development of epilepsy, changes in motor function, and development of long-lasting symptons since participation in the primary study.
Medical Record Review at 12 months
To assess medical status and the potential for new onset seizures, development of epilepsy, changes in motor function, and development of long-lasting symptons since participation in the primary study.
Change in tDCS Subject Report of Symptoms Questionnaire
Summary table of symptoms participant has experienced since the primary study.
Change in Qualitative tDCS Tolerance Survey
Qualitative analysis to compare the participants feedback regarding the tDCS.
Change in Gross Motor Function Classification System
The gross motor function of children and young people with cerebral palsy is categorized into 5 different levels: Level 1 is the most independent movement (child can run and jump) to Level 5, the most dependent (transported in a manual wheelchair, for example)

Secondary Outcome Measures

Change in time to complete montage setup
To evaluate speed of device setup, time to complete montage set up will be measured. On the REDCap (Research Electronic Data Capture) survey, the researcher will click a "now" button that records the time to seconds at the beginning and end of montage set up. The lower time corresponds to ease in montage set up.
Change in contact quality (CQ)
SMARTscan™ contact quality is reported by the device throughout the stimulation and reflects quality of the stimulation delivery. Lower contact quality indicates the stimulation isn't being properly delivered. Changes in stimulation quality over the three active sessions using a Friedman test (non-parametric test for repeated measures) will be determined. Tests with a p-value of <0.05 will be considered significant.
Change in Box and Blocks assessment score
To evaluate the potential change in motor function, the Box and Blocks score will be measured before and after each active session. Motor function is not hypothesized to change due to the limited trials of active tDCS.

Full Information

First Posted
September 13, 2021
Last Updated
June 13, 2023
Sponsor
University of Wisconsin, Madison
search

1. Study Identification

Unique Protocol Identification Number
NCT05071586
Brief Title
Pediatric Teleneuromodulation
Official Title
Remotely Monitored Transcranial Direct Current Stimulation in Children With Cerebral Palsy
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 21, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Wisconsin, Madison

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study will explore using remotely monitored 'active' non-invasive brain stimulation in children with cerebral palsy. Participants will receive active non-invasive brain stimulation with synchronous safety monitoring and guided instruction with laboratory staff after appropriate training. Participants will be between 8-21 years old and have a diagnosis of hemiparetic cerebral palsy with a history of a perinatal stroke or brain bleed, and can expect to be in the study for 5 days.
Detailed Description
Current exploratory single site open label unblinded trial, will assess the feasibility, tolerability, and safety of active tDCS in the home setting under caregiver, safety monitor and remote investigator supervision and direction. The study population will consist of 10 participants between ages 8 - 21 years and 365 days with hemiparetic cerebral palsy and a history of a brain bleed or stroke. An estimated 3.6 per 1,000 births in the United States are affected by stroke or brain bleeds which can lead to Cerebral Palsy (CP), a developmental disorder associated with motor impairment. While, the majority of rehabilitation approaches focus on behavioral repetition to improve gait and upper extremity function, these therapies can require extensive practice times and extent of recovery is variable. Thus, there is a need for novel strategies which can optimize rehabilitation outcomes for this population. Brain development during childhood is characterized by heighted neuroplastic potential stressing the importance for intervention methods that harness neuroplasticity. Accordingly, several therapies are theoretically based in mechanisms of motor learning and use-dependent plasticity. Non-invasive brain stimulation (NIBS), specifically transcranial direct current stimulation (tDCS), provides an approach for modulation of neuroplasticity that is safe, inexpensive, and portable. Furthermore, rehabilitation approaches combined with tDCS have shown promise to improve motor function recovery and quality of life after stroke in adults. Integrating the application of NIBS may allow for enhanced rehabilitation during the enhanced neuroplastic period of childhood and NIBS has demonstrated promising outcomes in increasing the rate and extent of recovery. The Pediatric Neuromodulation laboratory has shown that in children with CP the use of tDCS is safe, feasible, and successful at modifying motor performance when in combination with other physical therapy interventions. tDCS is not currently available to subjects without taking part in the study. In this study, investigators plan to administer tDCS in the remote setting during a synchronous zoom call with trained laboratory members. To ensure the device is safely used in the home setting only during designated times, in the presence of a trained safety monitor. The safety monitor will bring the device to the session, oversee the safety of its use, and take it back to the laboratory after the session is complete. This intervention has the potential to improve motor rehabilitation outcomes and can offer telehealth access, which may reduce treatment cost and improve access to limited access to clinic or hospital facilities. This study has the potential to set the foundation for larger clinical trials studies evaluating the efficacy of remote tDCS combined with rehabilitation interventions in children. Ultimately, this will contribute to a wider reach in improving quality of life across the lifespan in children with CP. On Day #1 there will be a practice stimulation montage setup assessment. Before their session, a GMFCS and pediatric cognition survey will be completed with the investigative team. All participants will be asked to view instructional videos on how to perform the procedures. Parent/child pairs will perform the assessment by walking through the steps with the guidance of the lab team member via videoconferencing. Efficiency and quality of setup data will be collected. A setup ease/comfort survey will be completed upon completion of the stimulation montage setup. Days 2-5 will consist of sham/active stimulation in the home setting under caregiver, safety monitor, and remote investigator supervision and direction. Status surveys inquiring well-being will be conducted before, during, and after stimulation as well as a Box and Blocks motor function tests. At any time the participant perceives discomfort while dosing to 1.5mA the investigators will adapt and modify the stimulation intensity. Protocol Amendment Approved 6/7/2023: addition of an optional 6 and 12 month study visit.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cerebral Palsy (CP)
Keywords
Children with cerebral palsy, Remote transcranial direct current stimulation (tDCS), Non-invasive brain stimulation (NIBS)

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Children diagnosed with stroke/brain bleed
Arm Type
Experimental
Arm Description
Male and females aged 8 to 21 with established diagnosis of stroke/brain bleed who are US residents.
Intervention Type
Device
Intervention Name(s)
Soterix 1x1 tDCS LTE Stimulator Device Model 1401
Intervention Description
Participants will receive 20 minutes of 1.5 mA (Milliampere) transcranial direct current stimulation (tDCS) via Soterix 1x1 tDCS LTE Stimulator Device Model 1401 with a bilateral M1 montage.
Primary Outcome Measure Information:
Title
Status/Safety Assessment
Description
Before stimulation, the study team will work with the participant to fill out a status survey. In the survey, participants will be asked to report the severity of events they may experience. Since investigators are working with the pediatric population, the investigator makes the final decision on the likelihood of an event being related to the tDCS intervention versus the participant's environment. Serious adverse events, falling in the 3-5 categories (1-unrelated, 2- unlikely, 3- possible, 4- probable, 5- definite) will be considered related to the study. This determination is made with the parent/caregiver as witnesses and confirmed by the parent/caregiver.
Time Frame
Baseline - Day 1
Title
Status/Safety Assessment
Description
During stimulation, the study team will work with the participant to fill out a status survey. In the survey, participants will be asked to report the severity of events they may experience. Since investigators are working with the pediatric population, the investigator makes the final decision on the likelihood of an event being related to the tDCS intervention versus the participant's environment. Serious adverse events, falling in the 3-5 categories (1-unrelated, 2- unlikely, 3- possible, 4- probable, 5- definite) will be considered related to the study. This determination is made with the parent/caregiver as witnesses and confirmed by the parent/caregiver.
Time Frame
During stimulation on days 2-5
Title
Status/Safety Assessment
Description
After stimulation, the study team will work with the participant to fill out a status survey. In the survey, participants will be asked to report the severity of events they may experience. Since investigators are working with the pediatric population, the investigator makes the final decision on the likelihood of an event being related to the tDCS intervention versus the participant's environment. Serious adverse events, falling in the 3-5 categories (1-unrelated, 2- unlikely, 3- possible, 4- probable, 5- definite) will be considered related to the study. This determination is made with the parent/caregiver as witnesses and confirmed by the parent/caregiver.
Time Frame
Posttest on sessions 2, 3, 4, and 5
Title
Change in tDCS headgear location
Description
To evaluate the quality of device setup, we will measure any changes or movement of the headgear. To do this, we will mark the starting and ending location of the headgear and measure the distance between the two. It will be reported if the headgear moved in any participants and the average displacement.
Time Frame
Post sessions on day 1, 2, 3, 4 , and 5
Title
Change in responses to ease of set up survey
Description
To evaluate the feasibility of remotely monitored-tDCS, the difficulty of each step will be measured on an ordinal 3-point scale. A lower score will correspond with a lower difficulty setting. Average difficulty will be compared throughout all sessions to indicate any improvement throughout the study.
Time Frame
Post sessions on day 1, 2, 3, 4 , and 5
Title
Change in responses to comfort survey
Description
To evaluate the comfort of the device, participants will be asked a question on an ordinal 4-point scale. A lower score corresponds with a higher comfortability.
Time Frame
Post sessions on day 1, 2, 3, 4 , and 5, optional 6 month follow up, optional 12 month follow up
Title
Medical Record Review at 6 months
Description
To assess medical status and the potential for new onset seizures, development of epilepsy, changes in motor function, and development of long-lasting symptons since participation in the primary study.
Time Frame
Optional 6 month follow up
Title
Medical Record Review at 12 months
Description
To assess medical status and the potential for new onset seizures, development of epilepsy, changes in motor function, and development of long-lasting symptons since participation in the primary study.
Time Frame
Optional 12 month follow up
Title
Change in tDCS Subject Report of Symptoms Questionnaire
Description
Summary table of symptoms participant has experienced since the primary study.
Time Frame
optional 6 and 12 month follow up
Title
Change in Qualitative tDCS Tolerance Survey
Description
Qualitative analysis to compare the participants feedback regarding the tDCS.
Time Frame
optional 6 and 12 month follow up
Title
Change in Gross Motor Function Classification System
Description
The gross motor function of children and young people with cerebral palsy is categorized into 5 different levels: Level 1 is the most independent movement (child can run and jump) to Level 5, the most dependent (transported in a manual wheelchair, for example)
Time Frame
baseline, optional 6 and 12 month follow up
Secondary Outcome Measure Information:
Title
Change in time to complete montage setup
Description
To evaluate speed of device setup, time to complete montage set up will be measured. On the REDCap (Research Electronic Data Capture) survey, the researcher will click a "now" button that records the time to seconds at the beginning and end of montage set up. The lower time corresponds to ease in montage set up.
Time Frame
Pre-stimulation on day 1, 2, 3, 4 and 5
Title
Change in contact quality (CQ)
Description
SMARTscan™ contact quality is reported by the device throughout the stimulation and reflects quality of the stimulation delivery. Lower contact quality indicates the stimulation isn't being properly delivered. Changes in stimulation quality over the three active sessions using a Friedman test (non-parametric test for repeated measures) will be determined. Tests with a p-value of <0.05 will be considered significant.
Time Frame
Post stimulation on day 1, 2, 3, 4 and 5
Title
Change in Box and Blocks assessment score
Description
To evaluate the potential change in motor function, the Box and Blocks score will be measured before and after each active session. Motor function is not hypothesized to change due to the limited trials of active tDCS.
Time Frame
Post sessions on day 2, 3, 4 , and 5, optional 6 month follow up, optional 12 month follow up

10. Eligibility

Sex
All
Minimum Age & Unit of Time
8 Years
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged between 8 years 0 days and 21 years 365 days Children who have hemiparetic cerebral palsy with a history of perinatal brain bleed/stroke Receptive language function to follow two-step commands Able to give informed assent along with the informed consent of the legal guardian. If the participant is 18-21 (with the capacity to consent), they must be able to give informed consent. Intentional about representing the sub-population of children with CP who experience intellectual disability (at least 2/10 participants with mild intellectual disabilities will be recruited) ≥ 10 degrees of active motion at the metacarpophalangeal joint Children who have had surgeries, which may influence motor function e.g.- tendon transfer, will be included, yet surgical history will be documented and included in any publication within a participant characteristics table. Exclusion Criteria: Inaccessibility to internet and a working computer/laptop/device. Implants Neoplasm Metabolic Disorders Epilepsy Seizure within two years preceding the study Acquired Traumatic Brain Injury Pregnancy Indwelling metal or incompatible medical devices Evidence of skin disease or skin abnormalities Botulinum toxin or Phenol block within [six-months] preceding the study Disorder of Cellular Migration and Proliferation To be eligible for the optional 6-month/12-month follow-up: participants must have previously participated in the primary study have access to a reliable internet connection and a functioning computer, laptop, or mobile device. If participants become pregnant after participating in primary study, they may participate in the 6- and 12-month follow up sessions
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bernadette Gillick, PhD, MSPT
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Wisconsin
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53705
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
33132132
Citation
Lench DH, Simpson E, Sutter EN, Gillick BT. Feasibility of remote transcranial direct current stimulation for pediatric cerebral palsy during the COVID-19 pandemic. Brain Stimul. 2020 Nov-Dec;13(6):1803-1804. doi: 10.1016/j.brs.2020.10.010. Epub 2020 Oct 23. No abstract available.
Results Reference
background
PubMed Identifier
36175848
Citation
Simpson EA, Saiote C, Sutter E, Lench DH, Ikonomidou C, Villegas MA, Gillick BT. Remotely monitored transcranial direct current stimulation in pediatric cerebral palsy: open label trial protocol. BMC Pediatr. 2022 Sep 29;22(1):566. doi: 10.1186/s12887-022-03612-8.
Results Reference
derived

Learn more about this trial

Pediatric Teleneuromodulation

We'll reach out to this number within 24 hrs